MedImmune, Inc.

FluMist maker acquires rights to reverse genetics patent

Published in Lab Law Weekly, January 6th, 2006

MedImmune, Inc. (MEDI) announced it has acquired exclusive worldwide rights to certain intellectual property owned by Mount Sinai School of Medicine for reverse genetics, including U.S. patent Nos. 6,544,785 and 6,649,372.

With this license, MedImmune has further strengthened its patent estate to now either own or have exclusive licenses to all of the key intellectual property for this technology:

-Mount Sinai School of Medicine Plasmid Rescue Portfolio (WO 01/04333)

-MedImmune Fundamental Reverse Genetics Portfolio (WO 91/03552)

-Wisconsin Alumni Research Foundation Plasmid Rescue Portfolio (WO...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2006-01-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry